The definition of biochemical failure in patients treated with definitive radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 5, 2000, Pages 1469-1474

  Kattan, Michael W ^a,b   Fearn, Paul A ^a   Leibel, Steven ^a   Potters, Louis ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Internal Medicine   (United States)

Author keywords

Brachytherapy; Prostate cancer; Radiotherapy

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; DATA BASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE RISK; STATISTICAL ANALYSIS; TREATMENT FAILURE;

BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; SOCIETIES, MEDICAL; TIME FACTORS; TREATMENT FAILURE;

EID: 0034564126     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)01359-6     Document Type: Article

References (12)

1. Consensus statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel
2. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer
3. Caution in interpreting biochemical control rates after treatment of prostate cancer; Length of follow-up influences results
4. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness
5. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer
6. Risk profiles to predict PSA relapse free survival for patients undergoing permanent prostate brachytherapy
7. Nonparametric estimation from incomplete observations
8. Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer
9. Prostate-specific antigen nadir; The optimum level after irradiation for prostate cancer
10. Prostate specific antigen nadir; The optimum level after irradiation for prostate cancer
11. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma
12. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostatic cancer treated with external beam irradiation